Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry

Abstract

Background: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation. In clinical studies, dupilumab reduced the risk of severe asthma exacerbations, and improved forced expiratory volume in 1 s and quality of life in patients with uncontrolled moderate-to-severe asthma. R. Gall (&)

Real-World Characteristics of Patients with Severe Asthma prior to Starting Dupilumab: The ProVENT Study

“…It might also be difficult to control patient behavior and adherence to therapy. Despite these limitations, the ProVENT study may provide valuable evidence on the effectiveness of biologics in patients with severe asthma, like other real-world studies and registries [19‒22, 31‒33].…”

Baseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global Registry

“…The full design of the RAPID study has been previously published. 10 The initial approving ethics institution was Advarra, 6100 Merriweather Dr., Suite 600, Columbia, MD 21044 and in participating countries, the appropriate ethics committee approvals or institutional review boards were granted for RAPID and all patients provided written informed consent. Between March 6, 2020 and October 28, 2021, 205 patients were enrolled in the RAPID registry at 47 sites in Denmark, Sweden, and the USA, including Puerto Rico.…”